Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Hemangiosarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Surveys and Questionnaires 2spartalizumab 1necitumumab 1Talc 1Nivolumab 1Immunotherapy 1Health Records, Personal 1Gemcitabine 1Drug Delivery Systems 1Carboplatin 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lung Diseases × spartalizumab × Clear all
NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡